Trial Profile
A Double-Blind, Randomized, Placebo-controlled Multicenter Trial of GRanulocyte-Macrophage Colony-stimulating Factor Administration to Decrease ICU Acquired Infections in Sepsis-induced ImmunoDepression
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Sepsis; Septic shock
- Focus Therapeutic Use
- Acronyms GRID
- 17 Sep 2018 Status changed from recruiting to completed.
- 19 Jan 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018, as reported by ClinicalTrials.gov.
- 19 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.